Clonal hematopoiesis of indeterminate potential
MONDO:0100543A precancerous condition characterized by the presence of somatic mutations in bone marrow or peripheral blood cells in individuals who may be cytopenic but do not have morphologic evidence of hematologic neoplasia. Its prevalence rises with age and is found in approximately 10% of individuals aged 70 to 80. It is associated with an increased risk of hematologic neoplasia. Mutations in the DNMT3A, TET2, or ASXL1 genes are usually identified. Approximately 10%-40% of individuals with age-related clonal hematopoiesis will progress to meet the diagnostic criteria for clonal hematopoiesis of indeterminate potential.
29 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Blood condition may predict worse outcomes after heart attack
Knowledge-focused Not yet recruitingThis study investigates whether a condition called clonal hematopoiesis of indeterminate potential (CHIP), which is an age-related change in blood cells, is linked to more severe heart damage in people who have had a major heart attack (STEMI). Researchers will test blood samples…
Sponsor: Medical University Innsbruck • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Not yet recruitingThis study is a registry that will collect medical information and blood samples from 500 adults with myelodysplastic syndromes (MDS) and related conditions. The goal is to learn more about how these diseases develop and progress over time. Participants will not receive any exper…
Sponsor: Technische Universität Dresden • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Massive study to uncover hidden link between blood mutations and immune disorders
Knowledge-focused Not yet recruitingThis study will follow 5,000 adults with immune system problems to see if certain blood cell mutations (called clonal hematopoiesis) are linked to their condition. Researchers will track new cases of immune-related diseases over time. No treatments or drugs are tested—this is pur…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC